MGEN
(NASDAQ)
0.4823
-0.0632  (-13.10%)
Volume (24h): 582.86K Day Range: 0.4712 - 0.5200
Market Cap: 25.59M 52W Range: 0.3110 - 3.24
Mar-13-20 02:01PM Analysts Have Lowered Expectations For Miragen Therapeutics, Inc. After Its Latest ResultsSimply Wall St.
Mar-11-20 09:45PM Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Lags Revenue EstimatesZacks
08:05PM miRagen Reports Fourth Quarter and Full Year 2019 Financial ResultsGlobeNewswire
Mar-11-20 06:30PM Miragen Therapeutics, Inc. to Host Earnings CallACCESSWIRE
Mar-04-20 05:30PM Signal Genetics, Inc. (MGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks
Feb-20-20 01:00PM miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020GlobeNewswire
Feb-14-20 04:30PM Has Signal Genetics (MGEN) Outpaced Other Medical Stocks This Year?Zacks
Feb-07-20 02:00PM miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common StockGlobeNewswire
Feb-06-20 09:03PM miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common StockGlobeNewswire
Jan-31-20 03:41PM Company News for Jan 31, 2020Zacks
Jan-30-20 12:00PM miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual DiseaseGlobeNewswire
Jan-23-20 01:00PM miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming ConferencesGlobeNewswire
Dec-13-19 01:10PM The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing OfferBenzinga
Dec-12-19 12:38PM The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent WinBenzinga
Dec-11-19 09:05PM miRagen Announces Major Changes to Company’s StrategyGlobeNewswire
Nov-26-19 01:00PM miRagen to Present at the Evercore ISI HealthCONx Conference 2019GlobeNewswire
Nov-12-19 06:51PM Could Miragen Therapeutics, Inc.'s (NASDAQ:MGEN) Investor Composition Influence The Stock Price?Simply Wall St.
Nov-07-19 11:45PM Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Lags Revenue EstimatesZacks
09:01PM miRagen Reports Third Quarter 2019 Results and Provides Corporate UpdateGlobeNewswire
Oct-31-19 02:33PM Earnings Preview: Signal Genetics, Inc. (MGEN) Q3 Earnings Expected to DeclineZacks
Oct-28-19 01:00PM miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference TodayGlobeNewswire
Oct-22-19 12:00PM miRagen Therapeutics to Report Third Quarter 2019 Financial Results and Host a Conference CallGlobeNewswire
Oct-16-19 06:45AM miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel GrowthGlobeNewswire
Aug-15-19 12:00PM miRagen Therapeutics to Present a Corporate Overview at the Robert W. Baird & Co. 2019 Global Healthcare ConferenceGlobeNewswire
Aug-12-19 12:00PM miRagen Therapeutics to Present a Corporate Overview at the 2019 Wedbush Healthcare ConferenceGlobeNewswire
Aug-08-19 12:45AM Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue EstimatesZacks
Aug-07-19 08:05PM miRagen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate RestructuringGlobeNewswire
Jul-31-19 02:36PM Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out forZacks
Jul-24-19 12:00PM Miragen Therapeutics to Report Second Quarter 2019 Financial Results and Host a Conference Call on August 7thGlobeNewswire
Jun-21-19 05:45PM Some Miragen Therapeutics (NASDAQ:MGEN) Shareholders Have Copped A Big 66% Share Price DropSimply Wall St.
May-28-19 08:30PM miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare ConferenceGlobeNewswire
May-21-19 11:00AM miRagen Presents Preclinical Data in Pulmonary Fibrosis Using Second Generation microRNA-29 Replacement Product Candidate at the 2019 American Thoracic Society International ConferenceGlobeNewswire
May-08-19 10:35PM Signal Genetics, Inc. (MGEN) Reports Q1 Loss, Misses Revenue EstimatesZacks
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)